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Background: Diabetic patients have a higher risk of bladder cancer and benign prostatic hyperplasia (BPH).
Theoretically, BPH patients may have an increased risk of bladder cancer because residual urine in the bladder
surely increases the contact time between urinary excreted carcinogens and the urothelium. However, whether BPH
increases bladder cancer risk in patients with type 2 diabetes has not been studied.
Methods: The reimbursement databases of all Taiwanese diabetic patients under oral anti-diabetic agents or insulin
from 1996 to 2009 were retrieved from the National Health Insurance. An entry date was set at 1 January 2006 and
a total of 547584 men with type 2 diabetes were followed up for bladder cancer incidence until the end of 2009.
Incidences of bladder cancer for BPH by status and by duration were calculated and adjusted hazard ratios
(95% confidence intervals) were estimated by Cox regression. The effects of diabetes duration and medications
used for diabetic control in relation with bladder cancer risk were also evaluated by Cox regression in BPH men.
Results: The incidences were 258.77 and 69.34 per 100,000 person-years for patients with and without BPH,
respectively, adjusted hazard ratio 1.794 (1.572, 2.047). For BPH patients, those who underwent surgical procedures
for BPH had a higher incidence than those who did not (355.45 vs. 250.09 per 100,000 person-years), respective
adjusted hazard ratios: 2.459 (1.946, 3.109) and 1.709 (1.492, 1.958). The significantly higher risk could be
demonstrated for BPH of any duration: respective adjusted hazard ratios 1.750 (1.430, 1.605), 1.844 (1.543, 2.203),
2.011 (1.680, 2.406) and 1.605 (1.341, 1.921) for BPH <1, 1–3, 3–5 and ≥5 years versus patients without BPH.
Sensitivity analyses for patients aged ≥60 years and after excluding BPH patients with surgical procedures or
without surgical procedures, respectively, yielded similar results. In BPH men, diabetes duration was not significantly
related with bladder cancer; but metformin was consistently associated with a significantly lower risk, with adjusted
hazard ratio of 0.719 (0.590, 0.875) for all ages and 0.742 (0.604, 0.912) for age ≥60 years.
Conclusions: BPH is a significant risk factor for bladder cancer in men with type 2 diabetes. Metformin may protect
against bladder cancer in BPH men.
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Benign prostatic hyperplasia (BPH) is a common uro-
logical disorder in men. Its prevalence increases with age
and may affect 3 of 4 men in their sixties [1-3]. BPH
may cause gradual obstruction to the bladder outflow, lea-
ding to progressive severity in lower urinary tract symp-
toms such as frequency, urgency, nocturia, incomplete
voiding and weak urinary stream.
Residual urine in the bladder in patients with BPH
surely increases the contact time between urinary ex-
creted carcinogens and the urothelium. Therefore, theo-
retically, patients with BPH may have an increased risk
of bladder cancer. An animal study conducted in female
Wistar rats supported such a hypothesis. Matsumoto
et al. found that surgically induced partial bladder outlet
obstruction resulted in a greater incidence of bladder can-
cer induced by the carcinogen n-butyl-n-butanol nitrosa-
mine [4].
Human studies investigating the link between BPH and
bladder cancer are still sparse. Two early case–control stu-
dies suggested an increased risk [5,6]. A recent cohort stu-
dy recruiting 79280 Swedish men hospitalized for BPH
from 1964 to 1983 and following the patients until 1989
concluded that the overall risk of bladder cancer was not
increased with BPH, but patients who underwent trans-
urethral resection of the prostate had a significantly 47%
higher risk [7].
On the other hand, diabetes may affect the lower
urinary tract symptoms/functions [8-13], and patients
with type 2 diabetes may have a higher risk of BPH
[3,10,12,14-17]. A study estimated that men with higher
fasting glucose (>110 mg/dl vs. 110 mg/dl or less) or
with a diagnosis of diabetes may have a significantly
3-fold and 2.3-fold higher risk of BPH, respectively [14].
Actually, type 2 diabetes and BPH share several common
risk factors including aging, insulin resistance and obe-
sity [3]. Studies suggested that type 2 diabetes, obesity
and metabolic syndrome may all affect the growth of
BPH. For example, an earlier study showed that the an-
nual BPH growth rate for patients without and with type
2 diabetes was 0.928 ml/year and 1.385 ml/year, respect-
ively [17]. The Baltimore Longitudinal Study of Aging
suggested that prostate volume increased 0.41 ml with
each 1-kg/m2 increment of body mass index, and there
was a 3.5-fold higher risk of BPH comparing a body
mass index of ≥35 kg/m2 to that of <25 kg/m2 [14]. A
study in Turkish men showed that the growth rate of
total prostate in BPH patients with and without metabolic
syndrome was 1.0 ml/year and 0.64 ml/year, respectively
(P = 0.018) [18]. Therefore, the etiology underlying the de-
velopment of metabolic syndrome including diabetes and
obesity may also lead to the growth of prostate.
The number of diabetic patients has been increasing
dramatically all over the world in recent decades [19],and this is especially remarkable in the Asian popula-
tions [20]. It is estimated that the global number of dia-
betic patients will increase from 171 million in 2000 to
366 million in 2030; and most of these patients will be
seen in Asian countries, with an estimated number of 75
million in 2000 and 180 million in 2030 [19]. Recently,
patients with type 2 diabetes have been shown to carry
a higher risk of bladder cancer [21-24] and the use of
some anti-diabetic agents (e.g. pioglitazone) might be
associated with an increased risk [25-28]. However, whe-
ther BPH can be a risk factor for bladder cancer in the
diabetic patients has not been studied. An elucidation of
the association between BPH and bladder cancer is not
only an issue of scientific interest, it is also important for
the planning and implementing programs for the preven-
tion of bladder cancer, either by reducing the incidence of
diabetes and BPH or by early treatment of these diseases.
Therefore, the purpose of the present study was to evalu-
ate, in men with type 2 diabetes, whether BPH could be a
risk factor for bladder cancer.
Methods
Since March 1995 a compulsory and universal system of
health insurance (the so-called National Health Insu-
rance, NHI) was implemented in Taiwan. All contracted
medical institutes must submit computerized and stan-
dard claim documents for reimbursement. More than
99% of citizens are enrolled in the NHI, and >98% of the
hospitals nationwide are under contract with the NHI.
The average number of annual physician visits in Taiwan
is one of the highest around the world, at approximately
15 visits per year per capita in 2009.
The National Health Research Institute is the only in-
stitute approved, as per local regulations, for handling
the NHI reimbursement databases for academic research.
The databases contain detailed records on every visit for
each patient, including outpatient visits, emergency de-
partment visits and hospital admission. The databases also
include principal and secondary diagnostic codes, pre-
scription orders, and claimed expenses. The identification
information of the individuals was scrambled for the pro-
tection of privacy. Diabetes was coded 250.1-250.9, BPH
600, and bladder cancer 188, based on the International
Classification of Diseases, Ninth Revision, Clinical Modifi-
cation (ICD-9-CM).
We first retrieved the databases of all patients who
had been diagnosed as having diabetes and under treat-
ment with either oral anti-diabetic agents or insulin
during the period of 1996–2009 from the whole nation
(n = 1789776). The selected entry date was 1 January
2006. After excluding patients who had a diagnosis of
diabetes after the year 2006 (n = 342351), patients who
held a Severe Morbidity Card as having type 1 diabetes
(n = 7120, in Taiwan, patients with type 1 diabetes were
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diagnosis and they were waived for much of the co-pay-
ments), patients having a diagnosis of bladder cancer
before 2006 (n = 9555), those who died (n = 96320) or
withdrew from the NHI (n = 12502) before entry date,
duplicated identification number (n = 106), unclear in-
formation on date of birth or sex (n = 5122), and diabetic
patients without any reimbursement record after the
entry date (n = 235746), a total of 1094404 patients with
a diagnosis of type 2 diabetes and under therapy with
oral anti-diabetic agents or insulin were recruited. A fur-
ther exclusion of the female sex yielded 547584 men
with type 2 diabetes for the present study.
All comorbidities and covariates were determined as a
status/diagnosis before the entry date. The ICD-9-CM
codes for the comorbidities were [21,29,30]: nephropathy
580–589, urinary tract disease 590–599, hypertension
401–405, chronic obstructive pulmonary disease (a sur-
rogate for smoking) 490–496, cerebrovascular disease
430–438, ischemic heart disease 410–414, peripheral ar-
terial disease 250.7, 785.4, 443.81 and 440–448, eye dis-
ease 250.5, 362.0, 369, 366.41 and 365.44, dyslipidemia
272.0-272.4, heart failure 398.91, 402.11, 402.91, 404.11,
404.13, 404.91, 404.93 and 428, obesity 278, alcohol-
related diagnosis 291, 303, 535.3, 571.0, 571.1, 571.2,
571.3 and 980.0, non-alcohol-related chronic liver dis-
ease 570–573, 070 and 571.4 (excluding 571.0, 571.1,
571.2 and 571.3), and cancer other than bladder cancer
140–208 (excluding 188). Medications included rosiglita-
zone, pioglitazone, sulfonylurea, meglitinide, metformin,
acarbose, insulin, statin, fibrate, angiotensin-converting
enzyme inhibitor and/or angiotensin receptor blocker,
calcium channel blocker, non-steroidal anti-inflamma-
tory drugs, alpha-blockers, 5-alpha reductase inhibitors,
clopidogrel, ticlopidine, dipyridamole, cyclophosphamide
and diuretics. Baseline characteristics between patients
with and without BPH were compared by Chi-square test.
The incidence density of bladder cancer was calculated
for BPH by status and by duration of BPH diagnosis
(<1 year, 1–3 years, 3–5 years and ≥5 years) in patients
of all ages and in patients aged ≥60 years, respectively.
Patients with BPH were further categorized into two
subgroups: with and without receiving surgical proce-
dures for the treatment of BPH, including transurethral
incision of the prostate, transurethral resection of the
prostate, suprapubic prostatectomy or retropubic prosta-
tectomy. The numerator for the incidence was the num-
ber of patients with incident bladder cancer during the
4-year follow-up from 1 January 2006 until 31 December
2009, and the denominator was the person-years of fol-
low-up.
To compare whether patients with BPH had a higher
probability of visits to the urologists or receiving labo-
ratory examinations that might potentially lead to thediagnosis of bladder cancer, the frequencies of these
items between patients with and without BPH were ana-
lyzed by Chi square test, in all patients and in patients
aged ≥60 years, respectively. Laboratory examinations
included serum tumor markers (including carcinoem-
bryonic antigen, carbohydrate antigen 19–9, carbohydrate
antigen 125 and tissue polypeptide antigen), urine cyto-
logy, cystoscopy, urinalysis and bladder ultrasonography.
The nuclear matrix protein-22 and the bladder tumor
associated antigen tests for screening bladder cancer were
not reimbursed by the NHI; and therefore they could not
be considered in the analyses.
Cox proportional hazards regression was performed to
estimate the hazard ratios for bladder cancer for patients
with BPH vs. patients without BPH. The following mod-
els were created: 1) BPH vs. no BPH; 2) BPH without sur-
gical procedures, BPH with surgical procedures vs. no
BPH; and 3) BPH by duration (<1 year, 1–3 years,
3–5 years and ≥5 years) vs. no BPH. For sensitivity ana-
lyses, the Cox models were also created after excluding
patients with surgical procedures and without surgical
procedures, respectively, from the analyses. All models
were created for all ages and age ≥60 years, respectively.
Age, diabetes duration, comorbidities, medications and
potential detection examinations were all adjusted for in
the models.
To further evaluate the possible effects of diabetes
duration and medications used for diabetic control on
the risk of bladder cancer among the BPH men, add-
itional Cox regression models were created for the dia-
betic men with BPH for all ages and for age ≥60 years,
respectively. Age, comorbidities, medications other than
anti-diabetic drugs and potential detection examinations
were all adjusted for in these models.
Analyses were conducted using SAS statistical soft-
ware, version 9.1 (SAS Institute, Cary, NC). P < 0.05 was
considered statistically significant.
Results
Table 1 compares the baseline characteristics between
patients with BPH and those without. Patients with BPH
were older and had longer diabetes duration, higher rates
of comorbidities (except obesity and alcohol-related diag-
nosis), and higher rates of using medications and other
cancer.
Table 2 shows the crude incidence of bladder cancer
with regards to BPH status or duration. The incidence
was 69.34 per 100,000 person-years for patients without
BPH and was 258.77 per 100,000 person-years for pa-
tients with BPH. For BPH patients, those who underwent
a surgical procedure had a higher incidence than those
who had not received a surgical procedure (355.45 vs.
250.09 per 100,000 person-years). The incidence seemed
to increase with longer duration of BPH and peaked at
Table 1 Baseline characteristics by benign prostatic hyperplasia
Variables BPH (−) BPH (+) P value
n % n % (Chi-square test)
n = 547584 465485 85.0 82099 15.0
Age (years)
<40 28373 6.1 103 0.1 <0.0001
40-49 88077 18.9 1692 2.1
50-59 144677 31.1 11014 13.4
60-69 106959 23.0 22785 27.8
≥70 97399 20.9 46505 56.7
Diabetes duration (years)
<1 43069 9.3 1921 2.3 <0.0001
1-3 83311 17.9 6379 7.8
3-5 7748 16.7 9061 11.0
≥5 261623 56.2 64738 78.9
Nephropathy 53002 11.4 19913 24.3 <0.0001
Urinary tract diseases 59012 12.7 33818 41.2 <0.0001
Hypertension 248296 53.3 63518 77.4 <0.0001
Chronic obstructive pulmonary disease 60418 13.0 25837 31.5 <0.0001
Cerebrovascular disease 59318 12.7 23756 28.9 <0.0001
Ischemic heart disease 95649 20.6 33370 40.7 <0.0001
Peripheral arterial disease 52064 11.2 18708 22.8 <0.0001
Eye disease 75016 16.1 24855 30.3 <0.0001
Dyslipidemia 231613 49.8 42928 52.3 <0.0001
Heart failure 25584 5.5 11400 13.9 <0.0001
Obesity 6360 1.37 779 0.95 <0.0001
Alcohol-related diagnosis 14797 3.18 1885 2.30 <0.0001
Non-alcohol-related chronic liver disease 155679 33.44 30421 37.05 <0.0001
Rosiglitazone 64221 13.8 16898 20.6 <0.0001
Pioglitazone 22241 4.8 5191 6.3 <0.0001
Sulfonylurea 365375 78.5 74154 90.3 <0.0001
Meglitinide 51909 11.2 14783 18.0 <0.0001
Metformin 325652 70.0 69254 84.4 <0.0001
Acarbose 68578 14.7 18395 22.4 <0.0001
Insulin 68122 14.6 20951 25.5 <0.0001
Statin 133169 28.6 26302 32.0 <0.0001
Fibrate 106427 22.9 19705 24.0 <0.0001
Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker 198383 42.6 52076 63.4 <0.0001
Calcium channel blocker 131769 28.3 40288 49.1 <0.0001
Non-steroidal anti-inflammatory drugs 303900 65.3 72262 88.0 <0.0001
Alpha-blockers 50456 10.84 69086 84.15 <0.0001
5-alpha reductase inhibitors 425 0.09 3409 4.15 <0.0001
Clopidogrel 14395 3.09 5346 6.51 <0.0001
Ticlopidine 11315 2.43 5278 6.43 <0.0001
Dipyridamole 78550 16.87 30566 37.23 <0.0001
Cyclophosphamide 456 0.10 147 0.18 <0.0001
Diuretics 103397 22.21 36462 44.41 <0.0001
Other cancer prior to baseline 41311 8.9 18433 22.5 <0.0001
BPH benign prostatic hyperplasia.
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% Person-years Incidence rate
(per 100,000 person-years)
All ages
I. BPH by status
No BPH 462432 1127 0.24 1625241.83 69.34
BPH 85152 742 0.87 286736.17 258.77
BPH/procedures (−) 78526 658 0.84 263103.83 250.09
BPH/procedures (+) 6626 84 1.27 23632.33 355.45
II. BPH by duration
All BPH patients
<1 year 16163 126 0.78 54808.83 229.89
1-3 years 23955 199 0.83 81308.00 244.75
3-5 years 20649 203 0.98 69799.92 290.83
≥5 years 24385 214 0.88 80819.42 264.79
BPH/procedures (−)
<1 year 12421 107 0.86 41550.17 257.52
1-3 years 23005 180 0.78 77899.17 231.07
3-5 years 19952 186 0.93 67255.08 276.56
≥5 years 23148 185 0.80 76399.42 242.15
BPH/procedures (+)
<1 year 3742 19 0.51 13258.67 143.30
1-3 years 950 19 2.00 3408.83 557.38
3-5 years 697 17 2.44 2544.83 668.02
≥5 years 1237 29 2.34 4420.00 656.11
Age ≥60 years
I. BPH by status
No BPH 201704 779 0.39 685559.17 113.63
BPH 71944 684 0.95 238880.17 286.34
BPH/procedures (−) 65952 605 0.92 217633.42 277.99
BPH/procedures (+) 5992 79 1.32 21246.75 371.82
II. BPH by duration
All BPH patients
<1 year 12864 111 0.86 42903.33 258.72
1-3 years 19405 182 0.94 64903.08 280.42
3-5 years 17536 193 1.10 58425.00 330.34
≥5 years 22139 198 0.89 72648.75 272.54
BPH/procedures (−)
<1 year 9567 93 0.97 31307.58 297.05
1-3 years 18529 164 0.89 61772.17 265.49
3-5 years 16885 176 1.04 56058.00 313.96
≥5 years 20971 172 0.82 68495.67 251.11
BPH/procedures (+)
<1 year 3297 18 0.55 11595.75 155.23
1-3 years 876 18 2.05 3130.92 574.91
3-5 years 651 17 2.61 2367.00 718.21
≥5 years 1168 26 2.23 4153.08 626.04
BPH benign prostatic hyperplasia, HR hazard ratio, CI confidence interval.
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went a surgical procedure. The findings were similar in
the analyses for those aged ≥60 years.
Table 3 compares the frequency of visits to urologists
and laboratory examinations that might potentially lead
to the diagnosis of bladder cancer in patients with and
without BPH. It is true that patients with BPH had a sig-
nificantly higher probability of potential detection bias.
The hazard ratios with regards to BPH by status or
duration are presented in Table 4. Except for BPH by
duration <1 year in the sensitivity analyses after exclud-
ing BPH patients without a surgical procedure from the
analyses, all hazard ratios showed a significantly higher
risk of bladder cancer associated with BPH. For analyses
in all patients of all ages, patients with BPH had a sig-
nificantly higher risk, with hazard ratio (95% confidence
interval): 1.794 (1.572, 2.047). BPH patients with a surgi-
cal procedure had a larger magnitude of hazard ratio
than those without: 2.459 (1.946, 3.109) vs. 1.709 (1.492,
1.958). The significantly higher risk could be demons-
trated in patients with BPH of any duration. The analysesTable 3 Comparison of the frequency of visits to
urologists and laboratory examinations potentially
leading to diagnosis of bladder cancer in patients with
and without benign prostatic hyperplasia
Variables Benign prostatic hyperplasia P value
No Yes
n % n %
All ages
Visits to urologists
No 427531 91.85 59460 72.42 <0.0001
Yes 37954 8.15 22639 27.58
Laboratory examinations*
No 119766 25.73 10354 12.61 <0.0001
Yes 345719 74.27 71745 87.39
Any of the above
No 116896 25.11 9309 11.34 <0.0001
Yes 348589 74.89 72790 88.66
Age ≥60 years
Visits to urologists
No 185836 90.94 50441 72.80 <0.0001
Yes 18522 9.06 18849 27.20
Laboratory examinations*
No 47633 23.31 8460 12.21 <0.0001
Yes 156725 76.69 60830 87.79
Any of the above
No 46463 22.74 7663 11.06 <0.0001
Yes 157895 77.26 61627 88.94
*Laboratory examinations include serum tumor markers, urine cytology,
cystoscopy, urinalysis and bladder ultrasonography.were similar in the sensitivity analyses, but the magnitudes
of hazard ratios were larger in patients with a surgical pro-
cedure than those without a surgical procedure in any
specific BPH duration (except for the category with BPH
duration <1 year).
Table 5 shows the adjusted hazard ratios for bladder
cancer with regards to diabetes duration and medica-
tions used for diabetic control in the diabetic men with
BPH. It was noted that diabetes duration was not signifi-
cantly related to bladder cancer in the BPH men; and
that among all anti-diabetic drugs only metformin was
significantly associated with a lower risk of bladder can-
cer in the BPH men.
Discussion
The present study strongly suggested that BPH is an im-
portant risk factor for bladder cancer in patients with
type 2 diabetes (Tables 2 and 4). Furthermore, BPH pa-
tients who had received a surgical procedure might have
a higher magnitude of hazard ratio than those without a
surgical procedure (Tables 2 and 4), suggesting that pa-
tients with more severe clinical conditions of BPH might
have a higher risk of bladder cancer. Although BPH
patients were older, had higher prevalences of most co-
morbidities and medications used (Table 1) and a higher
probability of detection bias (Table 3), the risk associated
with BPH could not be ascribed to these confounders
(Table 4). The effect of BPH on bladder cancer risk
seemed to be independent of diabetes because none of
the diabetes duration was significantly related with blad-
der cancer in the BPH men (Table 5). It was also ob-
served that, in the BPH men, those who used metformin
might have a significantly lower risk of bladder cancer
than those who had never used metformin (Table 5),
suggesting a potentially preventive effect of metformin
against bladder cancer development.
A possible explanation for a link between BPH and
bladder cancer is that the residual urine in the bladder
in patients with BPH may increase the time of urothelial
exposure to urinary excreted carcinogens. Such a hy-
pothesis is strongly supported by the animal study by
Matsumoto et al. because bladder cancer induced by the
carcinogen n-butyl-n-butanol nitrosamine may also be
aggravated by surgically induced bladder outlet obstruc-
tion in female Wistar rats [4]. Another circumstantial
evidence supporting the hypothesis in humans came from
prospective [31] and case–control [32] studies showing
that high fluid intake, indicating less concentrated urine
or more frequent micturition, was associated with a lower
risk of bladder cancer.
Patients with BPH also have a significantly higher risk
of chronic kidney disease, probably due to an obstructive
uropathy [33]. Chronic kidney disease has been consis-
tently proved to be a significant risk factor for bladder
Table 4 Hazard ratios for bladder cancer with regards to benign prostatic hyperplasia
BPH All ages Age ≥60 years
HR 95% CI P value HR 95% CI P value
All patients
N = 547584 N = 273648
I. BPH by status
1. BPH/procedures (−) or (+) 1.794 (1.572, 2.047) <0.0001 1.842 (1.600, 2.121) <0.0001
2. BPH/procedures (−) 1.709 (1.492, 1.958) <0.0001 1.753 (1.517, 2.027) <0.0001
BPH/procedures (+) 2.459 (1.946, 3.109) <0.0001 2.500 (1.960, 3.189) <0.0001
II. BPH by duration
<1 year 1.750 (1.430, 1.605) <0.0001 1.769 (1.425, 2.195) <0.0001
1-3 years 1.844 (1.543, 2.203) <0.0001 1.897 (1.571, 2.291) <0.0001
3-5 years 2.011 (1.680, 2.406) <0.0001 2.125 (1.760, 2.566) <0.0001
≥5 years 1.605 (1.341, 1.921) <0.0001 1.623 (1.343, 1.962) <0.0001
Sensitivity analyses
Excluding BPH with surgical procedure
N = 540958 N = 267656
I. BPH by status 1.740 (1.515, 1.740) <0.0001 1.797 (1.549, 2.084) <0.0001
II. BPH by duration
<1 year 1.943 (1.557, 2.425) <0.0001 1.975 (1.556, 2.507) <0.0001
1-3 years 1.756 (1.459, 2.112) <0.0001 1.813 (1.490, 2.207) <0.0001
3-5 years 1.913 (1.589, 2.304) <0.0001 2.025 (1.666, 2.462) <0.0001
≥5 years 1.474 (1.220, 1.780) <0.0001 1.506 (1.233, 1.839) <0.0001
Excluding BPH without surgical procedure
N = 469058 N = 207696
I. BPH by status 2.525 (1.984, 3.212) <0.0001 2.671 (2.078, 3.433) <0.0001
II. BPH by duration
<1 year 1.200 (0.760, 1.896) 0.4342 1.275 (0.796, 2.041) 0.3123
1-3 years 3.983 (2.477, 6.404) <0.0001 4.274 (2.614, 6.988) <0.0001
3-5 years 4.648 (2.818, 7.668) <0.0001 5.246 (3.163, 8.701) <0.0001
≥5 years 3.837 (2.588, 5.689) <0.0001 3.984 (2.621, 6.057) <0.0001
BPH benign prostatic hyperplasia, HR hazard ratio, CI confidence interval.
Models are adjusted for all variables in Table 1 and for potential detection examinations in Table 3.
The referent group in the models is patients without BPH.
Tseng BMC Cancer 2013, 13:7 Page 7 of 10
http://www.biomedcentral.com/1471-2407/13/7cancer in the Taiwanese population [21,34]. Therefore,
the increased risk of bladder cancer in patients with
BPH could also be partially explained by the higher inci-
dence of chronic kidney disease in these patients.
In the Swedish prospective follow-up study, there was
a lack of an overall risk of bladder cancer associated with
BPH [7], in contrary to a significant association in the
present study (Tables 2 and 4). There were several pos-
sible explanations. First, the Swedish study used the
bladder cancer incidence in the general population as
referents for the calculation of the standardized inci-
dence ratio. The referent groups would surely include
the BPH patients in the study and also include other
high risk patients like the diabetic patients who may
have an increased risk of bladder cancer [21-24]. Second,the Swedish study could not consider the adjustment for
potential confounders except for age. Furthermore, dif-
ferent ethnicities might also be a possible explanation. It
should be pointed out that the Swedish study did show a
significantly 2-fold higher risk of bladder cancer in a
subgroup of the BPH men who underwent transurethral
resection of the prostate and had genitourinary condi-
tions such as urinary tract infection and stones [7]. This
was consistent with the findings of the present study
(Tables 2 and 4), and with our previous study showing a
significantly higher risk of bladder cancer in patients
with a history of urinary tract infection or stones [21].
Although the etiology of BPH remains unknown, meta-
bolic disturbances may promote the growth of prostate.
Obesity, insulin resistance with elevated insulin level, and
Table 5 Hazard ratios for bladder cancer with regards to diabetes duration and medications used for diabetic control
in diabetic men with benign prostatic hyperplasia
All ages Age ≥60 years
HR 95% CI P value HR 95% CI P value
Diabetes duration
1-3 years vs. <1 year 0.992 (0.637, 1.546) 0.9731 1.117 (0.680, 1.835) 0.6610
3-5 years vs. <1 year 0.735 (0.471, 1.147) 0.1748 0.893 (0.546, 1.461) 0.6534
≥5 years vs. <1 year 0.679 (0.449, 1.027) 0.0664 0.784 (0.494, 1.246) 0.3035
Medications for diabetic control
Rosiglitazone (Yes vs. No) 1.124 (0.923, 1.369) 0.2443 1.115 (0.908, 1.370) 0.2994
Pioglitazone (Yes vs. No) 1.023 (0.752, 1.393) 0.8846 1.066 (0.774, 1.467) 0.6959
Sulfonylurea (Yes vs. No) 0.939 (0.742, 1.190) 0.6035 0.940 (0.734, 1.205) 0.6252
Meglitinide (Yes vs. No) 1.133 (0.934, 1.375) 0.2057 1.170 (0.958, 1.428) 0.1239
Metformin (Yes vs. No) 0.719 (0.590, 0.875) 0.0010 0.742 (0.604, 0.912) 0.0046
Acarbose (Yes vs. No) 1.045 (0.866, 1.261) 0.6471 1.034 (0.850, 1.258) 0.7407
Insulin (Yes vs. No) 0.893 (0.738, 1.081) 0.3465 0.880 (0.721, 1.073) 0.2062
HR hazard ratio, CI confidence interval.
Models are adjusted for all variables in Table 1 and for potential detection examinations in Table 3.
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are associated with a significantly higher risk of BPH
[3,35,36]. Obesity and diabetes are also associated with
systemic inflammation and oxidative stress, which may
promote the inflammatory processes in the prostate, lead-
ing to clinical development of BPH [3]. The link between
BPH and some lifestyle risk factors of type 2 diabetes such
as physical inactivity and dietary factors including in-
creased total energy intake and less vegetables or vitamin
D [3,15] also strongly support the existence of some com-
mon underlying etiology for BPH and type 2 diabetes,
which may well explain the observed association between
BPH and type 2 diabetes.
Diabetic patients have an increased risk of bladder
cancer [21-24]. The etiology for such a link has not yet
been clarified. Some possible mechanisms have been
proposed based on elevated blood glucose, insulin resist-
ance, elevated levels of insulin and insulin-like growth
factor-I, higher prevalences of neurogenic bladder and
sympathetic nerve dysfunction in the diabetic patients
[12]. Some recent studies also suggested a possible higher
risk of bladder cancer associated with the use of pioglita-
zone in patients with type 2 diabetes [25-28]. The present
study suggested another possible mechanism, which acts
through BPH in the diabetic patients.
There are several important clinical implications from
the present study. First, BPH-related bladder cancer can
be preventable if BPH is prevented or adequately treated
at its early stage. Second, in diabetic men with BPH, the
use of metformin is potentially preventive for the devel-
opment of bladder cancer. This finding surely provides a
good rationale for the conduction of clinical trials evalu-
ating the use of metformin for the prevention of bladdercancer among high-risk patients with BPH. Third, type 2
diabetes is increasing more remarkably in men than in
women in the Taiwanese younger generation in recent 2
decades, probably due to the increasing epidemic of
obesity in the young men [37,38]. It is expected that the
incidence of bladder cancer in the male population will
be increasing in the future when these young and obese
diabetic patients become older, because of the link be-
tween diabetes and BPH and the higher risk of bladder
cancer related to BPH as shown in the present study.
Therefore lifestyle modification to reduce the incidence
of obesity, diabetes and metabolic syndrome is man-
datory not only for preventing the development of BPH,
but also for reducing the incidence of bladder cancer.
Fourth, the potential confounding effect of BPH should
not be neglected while evaluating the association between
some medications and bladder cancer risk. For examples,
most recent studies evaluating the risk of bladder cancer
related to pioglitazone have not seriously considered such
a potential confounding from BPH and therefore their
conclusion of a positive link could be challenged with a
lack of such an adjustment for BPH. Furthermore, an
increased risk of bladder cancer has been warned for a
new class of oral anti-diabetic agents being under consid-
eration for approval for human use, i.e., the sodium-
dependent glucose cotransporter 2 inhibitors with a novel
mechanism of inhibiting glucose reabsorption from the
kidney [39]. It is strongly suggested that the potential con-
founding effect of BPH on bladder cancer risk should be
assessed during the evaluation for its approval.
Because all diabetic patients were treated with oral
anti-diabetic medications or insulin at entry, the chance
of misclassification of diabetes was actually very low.
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classification of bladder cancer and BPH. The probability
of misclassification of bladder cancer must be low, be-
cause labeled diagnoses should be printed out in all
prescriptions handed to the patients. Mislabeling of a
cancer diagnosis would not be acceptable to the patients
when they saw the diagnosis. With regards to the mis-
classification of BPH, this might not occur in patients
who had received a surgical procedure. Our analyses in
different subgroups of the BPH patients (Tables 2 and 4)
did not favor a possible impact resulting from such a
misclassification. It should be stressed that underdiagno-
sis of BPH was possible, especially when it was in the
early stage without remarkable symptoms. However, if
BPH increased the risk of bladder cancer, a misclassifica-
tion of patients with BPH in the referent group would
only have underestimated the hazard ratios.
Because the databases were derived from the whole
population and they spanned the whole period from the
beginning of the NHI to the end of 2009, there was no
concern of potential selection bias related to sampling
error. The longitudinal nature of the study and the use
of medical records reduced the likelihood of reverse
causality and recall bias. However, it should also be
mentioned that the local law restricts to retrieve only a
certain percentage of the reimbursement data from the
whole NHI databases for academic research. Therefore,
it was not possible for the present study to include the
detailed information on surgical procedures for bladder
cancer and additional data from non-diabetic general
population for more in-depth analyses on the use of total
cystectomy as a surrogate for “invasive bladder cancer”
and for a comparison of bladder cancer risk associated
with BPH in non-diabetic Taiwanese men, respectively.
Smoking is an important risk factor for bladder cancer
[40], but we did not have information of smoking for ad-
justment and could only consider surrogates that are
highly related to smoking, such as chronic obstructive
pulmonary disease, ischemic heart disease, cerebrovascu-
lar disease and peripheral arterial disease (Table 4). Theor-
etically, a confounder should be correlated simultaneously
with both the exposure (BPH) and the outcome (bladder
cancer), and it should not be an intermediate between ex-
posure and outcome [41]. There is no evidence showing
smoking as a determinant for BPH [2,15,16].
This study has several strengths. The databases in-
cluded all claim records on outpatient visits, emergency
department visits and hospital admission, and we caught
the diagnoses from all sources. Cancer is considered a se-
vere morbidity by the NHI and most medical co-pay-
ments can be waived. Furthermore, there is a low drug
cost-sharing required by the NHI and patients with cer-
tain conditions such as low-income household, veterans
or patients with prescription refills for chronic disease areexempted from the drug cost-sharing [42]. Therefore the
detection rate of bladder cancer would not tend to differ
among different social classes.
The study limitations included a lack of actual mea-
surement data for confounders such as obesity, smoking,
alcohol drinking, water intake, family history, lifestyle,
diet, hair dye use, and some occupational exposure and
genetic parameters. In addition, we did not have bio-
chemical data for evaluating their impact. Another li-
mitation is the lack of information on the grading and
staging of bladder cancer.
Conclusions
This population-based cohort study in Taiwan suggests
that BPH is a significant risk factor for bladder cancer in
men with type 2 diabetes. Metformin may protect against
bladder cancer in the BPH men. This commonly seen risk
factor of BPH should not be neglected in future studies
evaluating bladder cancer risk.
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